MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Research
Written by / Agency / Source: NEC Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC - Proceeds to Support Scaling and Advancement of Precision Medicine Computing Platform for Cancer Treatment - BostonGene.com / NEC.com
Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC

 

NewswireToday - /newswire/ - Tokyo, Japan, 2019/04/25 - Proceeds to Support Scaling and Advancement of Precision Medicine Computing Platform for Cancer Treatment - BostonGene.com / NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

NEC Corporation and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, today announced a US$50M series A strategic investment in BostonGene by NEC.

BostonGene, a pioneer in the use of biomedical software for advanced patient analysis, has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno- and targeted therapies. BostonGene's solution includes:

• Genome and transcriptome sequencing methods to create a patient's molecular profile.
• Algorithms that estimate the immune fitness and cancer characteristics of a patient.
• A continuously updated expert-curated and Artificial Intelligence (AI)-driven database of cancer research and clinical information.
• Cloud-native software that delivers a patient-prioritized list of best treatment options based on comprehensive data analysis of the tumor and its microenvironment.

Founded in 2015, BostonGene has evaluated its solution utilizing extensive data in close collaboration with many leading cancer centers across the U.S., and has a robust intellectual property portfolio.

The funding will allow BostonGene to accelerate its long-term strategy, enable the expansion of the company's development efforts, advance its collaboration programs, and support the growth of its talented and diverse team.

"As demonstrated by its remarkable growth and early widespread adoption, BostonGene is leading the precision medicine market in the innovation and development of a mission-critical computing platform," said Osamu Fujikawa, Senior Vice President and Head of the Business Innovation Unit at NEC Corporation. "NEC and BostonGene share a common vision of the immense potential of an AI-driven approach to cancer immunotherapy. Leveraging the strengths of both companies we will be able to improve the survival rate and quality of life for cancer patients."

"Transforming and personalizing medicine, from treating a diagnosis to treating the person, is becoming a reality with BostonGene's unique breakthrough platform. Our early successes validate the market need and the potential of our solution to truly transform cancer treatment and dramatically improve patients' chances for survival and quality of life. An investment of this magnitude will support our vision, mission and strategy, as well as the formation of synergies with the NEC Health Tech business to create meaningful new opportunities," said Andrew Feinberg, President and CEO of BostonGene.

About NEC Corporation

NEC Corporation (nec.com) is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow.

About BostonGene Corporation

BostonGene Corporation (BostonGene.com) is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene's unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2019 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Research Most Recent Related Newswires:

Bruker Announces Acquisition of Preclinical and Molecular Imaging Research Software Provider PMOD Technologies, LLC
Rohde & Schwarz and Martin Luther University Halle-Wittenberg Establish Research Partnership
Bruker and Champalimaud Foundation Announce Collaboration to Develop Novel Ultra-High Field 18 Tesla Preclinical MRI System and Applications
Imec, UZ Leuven, KU Leuven, The Ghent University, Agilent, Western Digital and BlueBee Develop Unique Hybrid Cloud Platform
Digital Revolution - Naval Group, B<>com’s New Industrial Investor
Bruker and the Translational Metabolic Lab At Radboud University Announce the Establishment of A Joint Center of Excellence for Translational Omics
Rohde & Schwarz and Helmut Schmidt University Hamburg Conduct Joint Research
Imec Researcher Receives ERC Advanced Grant to Develop Ultra-bright Thin-film Light Sources and Lasers
DSM Sets Science-based Reduction Targets for Emissions
Novel Nanomaterial Promises Improvements in Batteries and Many More Sustainable Applications
OnePlanet, a New Dutch Innovation Center for Food, Health and Agricultural Technology
Sequential Infiltration Synthesis (SIS) Significantly Improves EUV Patterning
GE Research Awarded MM ARPA-E Project to Develop World’s 1st High-Voltage Silicon Carbide Super Junction Transistor
DSM Strengthens its Market-leading Position in the Development and Commercialization of Sustainable, Innovative Resins and Circular Economy Solutions
DSM and Starboard Collaboration Transforms Discarded Fishing Nets from Waste into High-end Surfboard Components

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Broadcast Microwave Services, Inc.

Visit  BizJobs.com





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)